EBOS GROUP LIMITED (EBO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBO

EBO - EBOS GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.84
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$19.373

04 Mar
2026

-0.447

OPEN

$19.65

-2.26%

HIGH

$19.69

352,237

LOW

$19.20

TARGET
$28.023 44.7% upside
Franking for last dividend paid out: 95%
OTHER COMPANIES IN THE SAME SECTOR
ACL . ALC . BMT . DOC . HLS . IDX . M7T . MPL . MVF . NHF . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
EBO: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 109.7 127.3 xxx
DPS (cps) xxx 112.9 104.8 xxx
EPS Growth xxx - 22.4% 16.0% xxx
DPS Growth xxx N/A - 7.2% xxx
PE Ratio xxx N/A 15.2 xxx
Dividend Yield xxx N/A 5.4% xxx
Div Pay Ratio(%) xxx 102.9% 82.3% xxx

Dividend yield today if purchased 3 years ago: 2.72%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 5.83

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - ex-div 49.19c (franking 95%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx109.7
DPS All xxxxxxxxxxxxxxx112.9
Sales/Revenue xxxxxxxxxxxxxxx12,266.9 M
Book Value Per Share xxxxxxxxxxxxxxx1,348.0
Net Operating Cash Flow xxxxxxxxxxxxxxx418.5 M
Net Profit Margin xxxxxxxxxxxxxxx1.75 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx8.29 %
Return on Invested Capital xxxxxxxxxxxxxxx5.70 %
Return on Assets xxxxxxxxxxxxxxx3.07 %
Return on Equity xxxxxxxxxxxxxxx8.29 %
Return on Total Capital xxxxxxxxxxxxxxx10.08 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx156.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx82 M
Long Term Debt xxxxxxxxxxxxxxx1,540 M
Total Debt xxxxxxxxxxxxxxx1,622 M
Goodwill - Gross xxxxxxxxxxxxxxx2,245 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx184 M
Price To Book Value xxxxxxxxxxxxxxx2.64

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx146.0 M
Capex % of Sales xxxxxxxxxxxxxxx1.19 %
Cost of Goods Sold xxxxxxxxxxxxxxx11,346 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx497 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx95 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

26/02/2026

1

Upgrade to Buy from Neutral

$26.00

34.21%

EBOS Group’s 1H26 revenue came in 4% ahead of the consensus estimate, driven by Healthcare and Animal Care. The core earnings (EBITDA) margin of 4.4% missed by around -30bps and fell sequentially, highlights the analyst.

Citi attributes the margin pressure to duplicated distribution centre costs and a mix shift to higher-priced drugs, but points out FY26 earnings (EBITDA) guidance of $615-$635m was maintained.

The broker expects lower profit growth than consensus in FY27 before acceleration in FY28.

Citi lifts its FY27-29 earnings forecasts by 3-4% and upgrades to Buy from Neutral. Target of $26 is unchanged.

UBS

xx/xx/xxxx

1

xxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

05/03/2026

2

Overweight

-

-

First half results from Ebos Group were in line with Jarden's expectations and, "critically", management reaffirmed guidance for the full year.

This appears to be a transition year for the company before stronger growth and cash flow leverage returns in FY27, the broker adds.

The outstanding issue at the EPS level is the uplift in D&A and lease costs associated with the DC renewal coming on stream fully from FY27 onwards.

The broker reduces its target to NZ$34.00 from NZ$37.50. This mainly reflects higher lease cash flows. Overweight retained on valuation support and initial evidence the operating reset has now been completed.

FORECAST
Jarden forecasts a full year FY26 dividend of 105.00 cents and EPS of 126.00 cents.
Jarden forecasts a full year FY27 dividend of 106.00 cents and EPS of 129.10 cents.
Access Extra Coverage Research History >

EBO STOCK CHART

FNArena News on EBO

1
Australian Broker Call *Extra* Edition – Mar 05, 2026

1:29 PM - Daily Market Reports
2
Weekly Ratings, Targets, Forecast Changes – 27-02-26

Mar 02 2026 - Weekly Reports
3
FNArena Corporate Results Monitor – 26-02-2026

Feb 26 2026 - Australia
4
In Brief: EOS, Austral Resources & GLP-1 Winners

Feb 13 2026 - Weekly Reports
5
Weekly Ratings, Targets, Forecast Changes – 12-12-25

Dec 15 2025 - Weekly Reports

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps